Patents by Inventor Benjamin G. Keselowsky

Benjamin G. Keselowsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11491257
    Abstract: Embodiments of the present disclosure provide for structures including an alloy of calcium, strontium, and magnesium.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: November 8, 2022
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Michele Viola Manuel, Ida E. Svensson Berglund, Benjamin G. Keselowsky, Malisa Sarntinoranont, Harpreet Singh Brar, Hunter B. Henderson
  • Publication number: 20220106580
    Abstract: Described herein are targeted ChABC fusion proteins, complexes thereof, and uses thereof. The targeted ChABC fusion proteins can include a ChABC polypeptide that can be linked to a Gal-3 polypeptide. Monomer targeted ChABC fusion proteins can form homogeneous or heterogeneous complexes. The targeted ChABC fusion proteins and complexes thereof can be formulated as pharmaceutical formulations. The targeted ChABC fusion proteins, complexes thereof, and formulations thereof can be administered to a subject in need thereof.
    Type: Application
    Filed: October 25, 2019
    Publication date: April 7, 2022
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Gregory Allan Hudalla, Benjamin G. Keselowsky, Dillon T. Seroski, Shaheen A. Farhadi, Christine E. Schmidt, Nikunj Kumar Agrawal
  • Patent number: 10512607
    Abstract: Embodiments of the present disclosure include particles, methods of making particles, methods of delivering an active agent using the particle, and the like.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: December 24, 2019
    Assignees: Vanderbilt University, University of Florida Research Foundation, Inc.
    Inventors: Benjamin G. Keselowsky, Jamal Lewis, Lawrence Premasiri Fernando, Craig L. Duvall, Brian C. Evans, Lirong Yang
  • Publication number: 20190218264
    Abstract: Provided herein are targeted effector fusion proteins, complexes thereof, and uses thereof. The targeted effector fusion proteins can include an effector protein that can be linked to a targeting moiety. Monomer targeted effector fusion proteins can form homogeneous or heterogeneous complexes. The targeted effector fusion proteins and complexes thereof can be formulated as pharmaceutical formulations. The targeted effector fusion proteins, complexes thereof, and formulations thereof can be administered to a subject in need thereof.
    Type: Application
    Filed: October 4, 2017
    Publication date: July 18, 2019
    Inventors: GREGORY HUDALLA, SABRINA FREEMAN, ANTONIETTA RESTUCCIA, MARGARET FETTIS, EVELYN R. BRACHO-SANCHEZ, SHAHEEN FARHADI, BENJAMIN G. KESELOWSKY
  • Publication number: 20180258382
    Abstract: A biological cell and/or tissue growth apparatus operable to create, in a chamber of the apparatus, a three-dimensional (3D) cell culture and to interact with a 3D structure of the cells in the chamber to, for example, apply materials to and/or remove materials from the cells or the chamber. The apparatus may include equipment for printing the 3D cell culture in a 3D cell growth medium. The 3D cell growth medium may be a granular gel material that undergoes a temporary phase change in response to an applied stress, such as a thixotropic or “yield stress” material. The apparatus may be operated such that the 3D printing equipment “prints” the 3D cell culture by depositing cells at particular locations in the 3D cell growth medium.
    Type: Application
    Filed: September 16, 2016
    Publication date: September 13, 2018
    Inventors: BENJAMIN G. KESELOWSKY, THOMAS ETTOR ANGELINI, WALLACE GREGORY SAWYER, TAPOMOY BHATTACHARJEE
  • Patent number: 9913830
    Abstract: The present invention provides nanoparticle-coupled tolerogenic Treg cell therapy for treatment of immune and/or autoimmune disorders. In certain specific embodiments, the present invention can be used in the prevention and/or treatment of autoimmune diseases including, but not limited to, type 1 diabetes, lupus erythematosus (SLE), multiple sclerosis (MS), inflammatory bowel disease (IBD), rheumatoid arthritis, oophoritis, and autoimmune pathology associated with Graft versus Host Disease (GvHD) following hematopoietic stem cell transplantation.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: March 13, 2018
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Todd M. Brusko, Benjamin G. Keselowsky, Judit Cserny
  • Publication number: 20170119668
    Abstract: Embodiments of the present disclosure include particles, methods of making particles, methods of delivering an active agent using the particle, and the like.
    Type: Application
    Filed: October 25, 2016
    Publication date: May 4, 2017
    Inventors: Benjamin G. Keselowsky, Jamal Lewis, Lawrence Premasiri Fernando, Craig L. Duvall, Brian C. Evans, Lirong Yang
  • Publication number: 20170095590
    Abstract: Embodiments of the present disclosure provide for structures including an alloy of calcium, strontium, and magnesium.
    Type: Application
    Filed: December 16, 2016
    Publication date: April 6, 2017
    Inventors: Michele Manuel, Ida E. Svensson Berglund, Benjamin G. Keselowsky, Malisa Sarntinoranont, Harpreet Singh Brar, Hunter B. Henderson
  • Publication number: 20170080121
    Abstract: Disclosed herein is a non-toxic, bioresorbable, magnesium based alloy for use in production of implants. Specifically exemplified herein are alloy embodiments useful for orthopedic implants. Also disclosed are alloy materials that incorporate magnesium, calcium and strontium.
    Type: Application
    Filed: December 1, 2016
    Publication date: March 23, 2017
    Inventors: Michele Manuel, Harpreet Singh Brar, Ida E. Svensson Berglund, Malisa Sarntinoranont, Benjamin G. Keselowsky
  • Publication number: 20160175243
    Abstract: The subject invention concerns nanorods, compositions and substrates comprising nanorods, and methods of making and using nanorods and nanorod compositions and substrates. In one embodiment, the nanorod is composed of Zinc oxide (ZnO). In a further embodiment, a nanorod of the invention further comprises SiO2 or TiO2. In a specific embodiment, a nanorod of the invention is composed of ZnO coated with SiO2. Nanorods of the present invention are useful as an adhesion-resistant biomaterial capable of reducing viability in anchorage-dependent cells.
    Type: Application
    Filed: January 7, 2015
    Publication date: June 23, 2016
    Inventors: TANMAY P. LELE, FAN REN, BENJAMIN G. KESELOWSKY, JIYEON LEE, ANAND GUPTE, BYUNG-HWAN CHU, KARL R. ZAWOY
  • Publication number: 20140314866
    Abstract: The present invention provides nanoparticle-coupled tolerogenic Treg cell therapy for treatment of immune and/or autoimmune disorders. In certain specific embodiments, the present invention can be used in the prevention and/or treatment of autoimmune diseases including, but not limited to, type 1 diabetes, lupus erythematosus (SLE), multiple sclerosis (MS), inflammatory bowel disease (IBD), rheumatoid arthritis, oophoritis, and autoimmune pathology associated with Graft versus Host Disease (GvHD) following hematopoietic stem cell transplantation.
    Type: Application
    Filed: September 10, 2012
    Publication date: October 23, 2014
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION
    Inventors: Todd M. Brusko, Benjamin G. Keselowsky, Judit Cserny